Fosun Pharm Raises Holding in Tongjitang     

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharm, SH: 600196) announced March 10th that it have purchased aggregate 5 388 346 American depositary shares (ADSs) as of March 3rd, 2009 in Tongjitang Chinese Medicines Company (NYSE: TCM) via its fully-owned subsidiary Fosun Pharmaceutical (Hong Kong) Limited for US$16.93 million. As a result, Fosun Pharm raised the stake to 15.94% for TCM's total common shares.
   The Shanghai-based pharmaceuticals producer has lifted its holding in TCM for several times since October 2008 thanks to TCM's strong R & D ability and some products with high growth potential.
   Fosun Pharm, as one of China's leading medicine distributors, focuses on modern bio-medicine & health-care industry, with its core competences in R & D, manufacture, marketing and management.
   Guizhou-based Tongjitang Chinese Medicines, a leading specialty pharmaceutical company in China focusing on the development, manufacture, sales of modernized traditional Chinese medicines in China, with its osteoporosis treatment medicine - Xianling Gubao. Its ADSs has been traded on the New York Stock Exchange since March 16th, 2007.